New treatments for genotype 1 chronic hepatitis C - focus on simeprevir

Therapeutics and Clinical Risk Management

Volumn 10, Issue 1, 2014, Pages 387-394

  Kanda, Tatsuo ^a   Nakamoto, Shingo ^a   Wu, Shuang ^a   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

HCV NS3 4A protease inhibitor; Hepatitis C virus; Hepatocellular carcinoma; TMC435

Indexed keywords

PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PLACEBO; SIMEPREVIR; SOFOSBUVIR;

ADVERSE OUTCOME; CLINICAL EFFECTIVENESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84901508513     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S50170     Document Type: Review

References (49)

1. Ditah I, Ditah F, Devaki P, et al. The changing epidemiology of hepatitis C virus infection in the United States: national health and nutrition examination survey 2001 through 2010. J Hepatol. 2014;60(4):691-698.
2. Fenoglio L, Serraino C, Castagna E, et al. Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases. World J Gastroenterol. 2013;19(21):3207-3216.
3. Kim MN, Kim BK, Han KH. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region. J Gastroenterol. 2013;48(6):681-688.
4. Omata M, Kanda T, Yu ML, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int. 2012;6(2):409-435.
5. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5 Suppl 1):S35-S46.
6. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology. 1995;21(3):650-655.
7. Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int. 2010;4(3):548-561.
8. Kanda T, Nakamoto S, Nakamura M, et al. Direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection. J Clin Transl Hepatol. 2014;2(1):1-6.
9. D'Ambrosio R, Colombo M. Safety of direct antiviral agents in real life. Dig Liver Dis. 2013;45(Suppl 5):S363-S366.
10. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naïve patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56(1):78-84.
11. Tsantrizos YS. TMC-435, an NS3/4A protease inhibitor for the treatment of HCV infection. Curr Opin Investig Drugs. 2009;10(8):871-881.
12. Rosenquist A, Samuelsson B, Johansson PO, et al. Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor. J Med Chem. 2014;57(5):1673-1693.
13. Lin TI, Lenz O, Fanning G, et al. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother. 2009;53(4):1377-1385.
14. Moreno C, Berg T, Tanwandee T, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a Phase IIa, open-label study. J Hepatol. 2012;56(6):1247-1253.
15. Lenz O, Vijgen L, Berke JM, et al. Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202). J Hepatol. 2013;58(3):445-451.
16. Wu S, Kanda T, Nakamoto S, Imazeki F, Yokosuka O. Hepatitis C virus protease inhibitor-resistance mutations: our experience and review. World J Gastroenterol. 2013;19(47):8940-8948.
17. Lenz O, Verbinnen T, Lin TI, et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother. 2010;54(5):1878-1887.
18. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol. 2011;55(1):192-206.
19. Xue W, Pan D, Yang Y, Liu H, Yao X. Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435. Antiviral Res. 2012;93(1):126-137.
20. Lenz O, de Bruijne J, Vijgen L, et al. Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy. Gastroenterology. 2012;143(5):1176-1178.
21. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013;58(6): 1918-1929.
22. Hayashi N, Seto C, Kato M, Komada Y, Goto S. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol. 2014;49(1):138-147.
23. Wu S, Kanda T, Nakamoto S, et al. Prevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: ultra-deep sequencing analysis of HCV NS5B genotype-specific region. PLoS One. 2013;8(9):e73615.
24. Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a Phase IIb trial. Gastroenterology. 2014;146(2): 430-441.
25. Hayashi N, Izumi N, Kumada H, et al. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol. Epub 2014 Apr 9.
26. Izumi N, Hayashi N, Kumada H, et al. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol. 2014;49(5):941-953.
27. Suzuki F, Hayashi N, Goto S, Kumada H. Simeprevir with Peginterferon alpha-2b/Ribavirin for hepatitis C genotype 1 patients: the CONCERTO-4 study. Kanzo. 2014;54(suppl1):A157. Japanese.
28. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve patients: efficacy in difficult-to-treat patient sub-populations in the QUEST-1 and 2 Phase III trials [abstract]. Hepatology. 2013;58(Suppl 1):756A.
29. Forns X, Lawitz E, Zeuzem S, et al. Simeprevir (TMC435) with peginterferon α-2a/ribavirin for treatment of chronic HCV genotype 1 infection inpatients who relapsed after previous interferon-based therapy: efficacy and safety in patient sub-populations in the PROMISE Phase III trial [abstract]. Hepatology. 2013;58(Suppl 1):737A.
30. Janssen R&D Ireland. TMC435HPC3001-an efficacy, safety and tolerability study for TMC435 vs telaprevir in combination with pegINFα-2a and ribavirin in chronic hepatitis C patients who were null or partial responders to prior pegINFα-2a and ribavirin therapy (ATTAIN). Available from: http://clinicaltrials.gov/ct2/show/NCT01485991. NLM identifier: NCT01485991. Accessed February 10, 2014.
31. Jacobson IM, Ghalib RH, Rodriguez-Torres M, et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: the COSMOS study [abstract]. Hepatology. 2013;58(Suppl 6):1379A.
32. Kanda T, Yokosuka O, Omata M. Antiviral therapy for "difficult-to-treat" hepatitis C virus-infected patients. Chin Med J (Engl). 2013;126(23):4568-4574.
33. Sulkowski MS. HCV therapy in HIV-infected patients. Liver Int. 2013;33(Suppl 1):63-67.
34. Perez-Latorre L, Sanchez-Conde M, Rincon D, et al. Prediction of liver complications in patients with hepatitis C virus-related cirrhosis with and without HIV coinfection: comparison of hepatic venous pressure gradient and transient elastography. Clin Infect Dis. 2014;58(5): 713-718.
35. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438-450.
36. Chung RT, Andersen J, Volberding P, et al. Peginterferon α-2a plus ribavirin versus interferon α-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351(5):451-459.
37. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon α-2b vs standard interferon α-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292(23): 2839-2848.
38. Laguno M, Murillas J, Blanco JL, et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS. 2004;18(13):F27-F36.
39. Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med. 2013;159(2): 86-96.
40. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon α-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled Phase 2 trial. Lancet Infect Dis. 2013;13(7):597-605.
41. Martel-Laferriere V, Brinkley S, Bichoupan K, et al. Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. HIV Med. 2014;15(2):108-115.
42. Fierer DS, Dieterich DT, Mullen MP, et al. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis. 2014;58(6):873-879.
43. Highleyman L. EACS 2013: simeprevir with interferon effective for genotype 1 HIV/HCV coinfected people [webpage on the Internet]. San Francisco, CA: hivandhepatitis. com; 2013 [cited October 20, 2013]. Available from: http://www.hivandhepatitis.com/hcv-treatment/experimental-hcv-drugs/4367-eacs-2013-simeprevir-with-interferon-effective-for-hivhcv-coinfected-people-with-genotype-1-or-4. Accessed February 10, 2014.
44. Donlin MJ, Cannon NA, Yao E, et al. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol. 2007;81(15): 8211-8224.
45. Akuta N, Suzuki F, Hirakawa M, et al. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol. 2009;81(3):452-458.
46. Alestig E, Arnholm B, Eilard A, et al. Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection. BMC Infect Dis. 2011;11:124.
47. Soriano V, Poveda E, Vispo E, Labarga P, Rallon N, Barreiro P. Pharmacogenetics of hepatitis C. J Antimicrob Chemother. 2012;67(3): 523-529.
48. Nakamoto S, Imazeki F, Fukai K, et al. Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development. J Hepatol. 2010;52(1):72-78.
49. Maekawa S, Enomoto N. Once-daily simeprevir in combination with pegylated-interferon and ribavirin: a new horizon in the era of direct-acting antiviral agent therapy for chronic hepatitis C. J Gastroenterol. 2014;49(1):163-164.